Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins

Journal of Medicinal Chemistry

Volumn 51, Issue 21, 2008, Pages 6902-6915

  Park, Cheol Min ^a   Bruncko, Milan ^a   Adickes, Jessica ^a   Bauch, Joy ^a   Ding, Hong ^a   Kunzer, Aaron ^a   Marsh, Kennan C ^a   Nimmer, Paul ^a   Shoemaker, Alexander R ^a   Song, Xiaohong ^a   Tahir, Stephen K ^a   Tse, Christin ^a   Wang, Xilu ^a   Wendt, Michael D ^a   Yang, Xiufen ^a   Zhang, Haichao ^a   Fesik, Stephen W ^a   Rosenberg, Saul H ^a   Elmore, Steven W ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 [4 [(4'CHLOROBIPHENYL 2 YL)METHYL]PIPERAZIN 1 YL]N[3 CYANO 4 [4 (DIMETHYLAMINO) 1 (PHENYLTHIO)BUTAN 2 YLAMINO]PHENYLSULFONYL]BENZAMIDE TRIFLUOROACTIC ACID; 4 [4 [(4'CHLOROBIPHENYL 2 YL)METHYL]PIPERAZIN 1 YL]N[4 [4 (DIMETHYLAMINO) 1 (PHENYLTHIO)BUTAN 2 YLAMINO] 3 (2,2,2 TRIFLUOROACETYL)PHENYLSULFONYL]BENZAMIDE TRIFLUOROACTIC ACID; 4 [4 [(4'CHLOROBIPHENYL 2 YL)METHYL]PIPERAZIN 1 YL]N[4 [4 (DIMETHYLAMINO) 1 (PHENYLTHIO)BUTAN 2 YLAMINO] 3 (METHYLSULFONYL)PHENYLSULFONYL]BENZAMIDE TRIFLUOROACTIC ACID; 4 [4 [(4'CHLOROBIPHENYL 2 YL)METHYL]PIPERAZIN 1 YL]N[4 [4 (DIMETHYLAMINO) 1 (PHENYLTHIO)BUTAN 2 YLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)PHENYLSULFONYL]BENZAMIDE TRIFLUOROACTIC ACID; 4 [4 [(4'CHLOROBIPHENYL 2 YL)METHYL]PIPERAZIN 1 YL]N[4 [4 (DIMETHYLAMINO) 1 (PHENYLTHIO)BUTAN 2 YLAMINO] 3 METHYLPHENYLSULFONYL]BENZAMIDE; 4 [4 [(4'CHLOROBIPHENYL 2 YL)METHYL]PIPERAZIN 1 YL]N[4 [4 (DIMETHYLAMINO) 1 (PHENYLTHIO)BUTAN 2 YLAMINO]PHENYLSULFONYL]BENZAMIDE TRIFLUOROACTIC ACID; 4 [4 [[2 (4 CHLOROBIPHENYL) 5,5 DIMETHYLCYCLOHEX 1 ENYL]METHYL]PIPERAZIN 1 YL]N[4 [4 (DIMETHYLAMINO) 1 (PHENYLTHIO)BUTAN 2 YLAMINO] 3 NITROPHENYLSULFONYL]BENZAMIDE TRIFLUOROACTIC ACID; 4 [4 [[2 (4 CHLOROBIPHENYL) 5,6 DIHYDRO 2H PYRAN 3 YL]METHYL]PIPERAZIN 1 YL]N[4 [4 (DIMETHYLAMINO) 1 (PHENYLTHIO)BUTAN 2 YLAMINO] 3 NITROPHENYLSULFONYL]BENZAMIDE TRIFLUOROACTIC ACID; 4 [4 [[2 (4 CHLOROBIPHENYL)CYCLOHEPT 1 ENYL]METHYL]PIPERAZIN 1 YL]N[4 [4 (DIMETHYLAMINO) 1 (PHENYLTHIO)BUTAN 2 YLAMINO] 3 NITROPHENYLSULFONYL]BENZAMIDE TRIFLUOROACTIC ACID; 4 [4 [[2 (4 CHLOROBIPHENYL)CYCLOHEX 1 ENYL]METHYL]PIPERAZIN 1 YL]N[4 [4 (DIMETHYLAMINO) 1 (PHENYLTHIO)BUTAN 2 YLAMINO] 3 NITROPHENYLSULFONYL]BENZAMIDE TRIFLUOROACTIC ACID; 4 [4 [[2 (4 CHLOROBIPHENYL)CYCLOHEX 1 ENYL]METHYL]PIPERAZIN 1 YL]N[4 [4 MORPHOLINO (PHENYLTHIO)BUTAN 2 YLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)PHENYLSULFONYL]BENZAMIDE TRIFLUOROACTIC ACID; 4 [4 [[2 (4 CHLOROBIPHENYL)CYCLOOCT 1 ENYL]METHYL]PIPERAZIN 1 YL]N[4 [4 (DIMETHYLAMINO) 1 (PHENYLTHIO)BUTAN 2 YLAMINO] 3 NITROPHENYLSULFONYL]BENZAMIDE TRIFLUOROACTIC ACID; 4 [4 [[2 (4 CHLOROBIPHENYL)CYCLOPENT 1 ENYL]METHYL]PIPERAZIN 1 YL]N[4 [4 (DIMETHYLAMINO) 1 (PHENYLTHIO)BUTAN 2 YLAMINO] 3 NITROPHENYLSULFONYL]BENZAMIDE TRIFLUOROACTIC ACID; ABT 263; ANTINEOPLASTIC AGENT; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; TUMOR CELL; TUMOR REGRESSION; XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; CELL LINE; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; MOLECULAR STRUCTURE; PROTO-ONCOGENE PROTEINS C-BCL-2; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 56249144184     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800669s     Document Type: Article

References (40)

1. McDonald, E. R., III.; El-Deiry, W. S. Mammalian cell death pathways: intrinsic and extrinsic. Death Recept. Cancer Ther. 2005, 1-41.
2. Amundson, S. A.; Myers, T. G.; Scudiero, D.; Kitada, S.; Reed, J. C.; et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 2000, 60, 6101-6110.
3. Adams, J. M.; Cory, S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr. Opin. Immunol. 2007, 19, 488-496.
4. Youle, R. J.; Strasser, A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008, 9, 47-59.
5. van Delft, M. F.; Huang, D. C. How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res. 2006, 16, 2003-2013.
6. Shi, Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell 2002, 9, 459-470.
7. Fesik, S. W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 2005, 5, 995-995.
8. Elmore, S. W.; Oost, T. K.; Park, C.-M. Inhibitors of anti-apoptotic proteins for cancer therapy. Annu. Rep. Med. Chem. 2005, 40, 245-262.
9. Manion, M. K.; Fry, J.; Schwartz, P. S.; Hockenbery, D. M. Small-molecule inhibitors of Bcl-2. Curr. Opin. Invest. Drugs (Thomson Sci.) 2006, 7, 1077-1084.
10. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435, 677-681.
11. L from NMR and parallel synthesis. J. Med. Chem. 2006, 49, 656-663.
12. Wendt, M. D.; Shen, W.; Kunzer, A.; McClellan, W. J.; Bruncko, M.; et al. Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. J. Med. Chem. 2006, 49, 1165-1181.
13. Bruncko, M.; Oost, T. K.; Belli, B. A.; Ding, H.; Joseph, M. K.; et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J. Med. Chem. 2007, 50, 641-662.
14. Park, C.; Oie, T.; Petros, A.; Zhang, H.; Nimmer, P.; et al. Design, synthesis, and computational studies of inhibitors of Bcl-X(L). J. Am. Chem. Soc. 2006, 128, 16206-16212.
15. Tahir, S. K.; Yang, X.; erson, M. G.; Morgan-Lappe, S. E.; Sarthy, A. V.; et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res. 2007, 67, 1176-1183.
16. Chen, S.; Dai, Y.; Harada, H.; Dent, P.; Grant, S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 2007, 67, 782-791.
17. Kuroda, J.; Kimura, S.; Strasser, A.; Andreeff, M.; O'Reilly L. A.; Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ. 2007, 14, 1667-1677.
18. Kohl, T. M.; Hellinger, C.; Ahmed, F.; Buske, C.; Hiddemann, W.; et al. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia 2007, 8, 1763-1772.
19. Konopleva, M.; Contractor, R.; Tsao, T.; Samudio, I.; Ruvolo, P. P. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006, 10, 375-388.
20. van Delft, M. F.; Wei, A. H.; Mason, K. D.; Vandenberg, C. J.; Chen, L.; et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10, 389-399.
21. Tse, C.; Shoemaker, A. R.; Adickes, J.; erson, M. G.; Chen, J.; et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68, 3421-3428.
22. Cohen, N.; Weber, G.; Banner, B. L.; Lopresti, R. J.; Schaer, B.; et al. 3,4-Dihydro-2H-1-benzopyran-2-carboxylic acids and related compounds as leukotriene antagonists. J. Med. Chem. 1989, 32, 1842-1860.
23. Wolfe, J. P.; Buchwald, S. L. Scope and limitations of the Pd/BINAP-catalyzed animation of aryl bromides. J. Org. Chem. 2000, 65, 1144-1157.
24. Koshechko, V. G.; Kiprianova, L. A.; Fileleeva, L. I. A new convenient method for the synthesis of perfluoroalkylarylsulfides. Tetrahedron Lett. 1992, 33, 6677-6678.
25. Langlois, B. R. Improvement of the synthesis of aryl difluoromethyl ethers and thioethers by using a solid-liquid phase-transfer technique. J. Fluorine Chem. 1988, 41, 247-261.
26. Su, W. An efficient method for the oxidation of sulfides to sulfones. Tetrahedron Lett. 1994, 35, 4955-4958.
27. Villar, R.; Encio, I.; Migliaccio, M.; Gil, M. J.; Martinez-Merino, V. Synthesis and cytotoxic activity of lipophilic sulphonamide derivatives of the benzo[b]thiophene 1,1-dioxide. Bioorg. Med. Chem. 2004, 12, 963-968.
28. Arnold, Z.; Holy, A. Synthetic reactions of dimethylformamide. XIII. b-Bromoacrylalderrydes. Collect. Czech. Chem. Commun. 1961, 26, 3059-3073.
29. Zhang, H.; Nimmer, P.; Rosenberg, S. H.; Ng, S.; Joseph, M. Development of a high-throughput fluorescence polarization assay for Bcl-x(L). Anal. Biochem. 2002, 307, 70-75.
30. Certo, M.; Del Gaizo Moore, V.; Nishino, M.; Wei, G.; Korsmeyer, S.; et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006, 9, 351-365.
31. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
32. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; et al. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
33. Hansch, C.; Leo, A.; Unger, S. H.; Kim, K. H.; Nikaitani, D.; et al. Aromatic substituent constants for structure-activity correlations. J. Med. Chem. 1973, 16, 1207-1216.
34. Hansch, C.; Leo, A.; Taft, R. W. A survey of Hammett substituent constants and resonance and field parameters. Chem. Rev. 1991, 91, 165-195.
35. Lee, E. F.; Czabotar, P. E.; Smith, B. J.; Deshayes, K.; Zobel, K.; et al. Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ. 2007, 14, 1711-1713.
36. Rybak, M. J. Pharmacodynamics: relation to antimicrobial resistance. Am. J. Med. 2006, 119, S37-S44.
37. Wilson, W. H.; Tulpule, A.; Levine, A. M.; Dunleavy, K.; Krivoshik, A. P.; et al. A phase 1/2a study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. Blood (ASH Annu. Meet. Abstr.) 2007, 110, 1371.
38. Sattler, M.; Liang, H.; Nettesheim, D.; Meadows, R. P.; Harlan, J. E.; et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997, 275, 983-986.
39. Petros, A. M.; Medek, A.; Nettesheim, D. G.; Kim, D. H.; Yoon, H. S.; et al. Solution structure of the antiapoptotic protein bcl-2. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3012-3017.
40. Takahashi, T.; Sakuraba, A.; Hirohashi, T.; Shibata, T.; Hirose, M.; et al. Novel potent neuropeptide Y Y5 receptor antagonists: synthesis and structure-activity relationships of phenylpiperazine derivatives. Bioorg. Med. Chem. 2006, 14, 7501-7511.